Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury.

Heyne N, Denecke B, Guthoff M, Oehrlein K, Kanz L, Häring HU, Weisel KC.

Ann Hematol. 2012 May;91(5):729-735. doi: 10.1007/s00277-011-1383-0. Epub 2011 Dec 15.

PMID:
22170517
2.

Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis.

Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S, Hattersley J, Evans ND, Chappel MJ, Sampson P, Foggensteiner L, Adu D, Cockwell P.

Clin J Am Soc Nephrol. 2009 Apr;4(4):745-54. doi: 10.2215/CJN.04590908. Epub 2009 Apr 1.

3.

Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma.

Martín-Reyes G, Toledo-Rojas R, Torres-de Rueda Á, Sola-Moyano E, Blanca-Martos L, Fuentes-Sánchez L, Martínez-Esteban MD, Díez-de los Ríos MJ, Bailén-García A, González-Molina M, García-González I.

Nefrologia. 2012;32(1):35-43. doi: 10.3265/Nefrologia.pre2011.Nov.11094. English, Spanish.

4.

Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.

Hutchison CA, Heyne N, Airia P, Schindler R, Zickler D, Cook M, Cockwell P, Grima D.

Nephrol Dial Transplant. 2012 Oct;27(10):3823-8. doi: 10.1093/ndt/gfr773. Epub 2012 Jan 23.

PMID:
22273664
5.

Novel renal replacement strategies for the elimination of serum free light chains in patients with kappa light chain nephropathy.

Kleeberg L, Morgera S, Jakob C, Hocher B, Schneider M, Peters H, Rötzer S, Müller C, Kaiser M, Fleissner C, Heider U, Neumayer HH, Sezer O.

Eur J Med Res. 2009;14:47-54.

6.

Effectiveness of Haemodiafiltration with Heat Sterilized High-Flux Polyphenylene HF Dialyzer in Reducing Free Light Chains in Patients with Myeloma Cast Nephropathy.

Rousseau-Gagnon M, Agharazii M, De Serres SA, Desmeules S.

PLoS One. 2015 Oct 14;10(10):e0140463. doi: 10.1371/journal.pone.0140463. eCollection 2015.

7.

Impact of High-Cut-Off Dialysis on Renal Recovery in Dialysis-Dependent Multiple Myeloma Patients: Results from a Case-Control Study.

Gerth HU, Pohlen M, Görlich D, Thölking G, Kropff M, Berdel WE, Pavenstädt H, Brand M, Kümpers P.

PLoS One. 2016 May 6;11(5):e0154993. doi: 10.1371/journal.pone.0154993. eCollection 2016.

8.

Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.

Yadav P, Hutchison CA, Basnayake K, Stringer S, Jesky M, Fifer L, Snell K, Pinney J, Drayson MT, Cook M, Cockwell P.

Eur J Haematol. 2016 Jun;96(6):610-7. doi: 10.1111/ejh.12644. Epub 2015 Sep 16.

PMID:
26248588
9.
10.

Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.

Zannetti BA, Zamagni E, Santostefano M, De Sanctis LB, Tacchetti P, Mancini E, Pantani L, Brioli A, Rizzo R, Mancuso K, Rocchi S, Pezzi A, Borsi E, Terragna C, Marzocchi G, Santoro A, Cavo M.

Am J Hematol. 2015 Jul;90(7):647-52. doi: 10.1002/ajh.24035.

11.

Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.

Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Eleutherakis-Papaiakovou E, Migkou M, Matsouka C, Mparmparousi D, Gika D, Kafantari E, Ziogas D, Fotiou D, Panagiotidis I, Terpos E, Kastritis E.

Am J Hematol. 2016 May;91(5):499-502. doi: 10.1002/ajh.24335. Epub 2016 Apr 4.

12.

Impact of free light chain hemodialysis in myeloma cast nephropathy: a case-control study.

Peters NO, Laurain E, Cridlig J, Hulin C, Cao-Huu T, Frimat L.

Hemodial Int. 2011 Oct;15(4):538-45. doi: 10.1111/j.1542-4758.2011.00587.x. Epub 2011 Aug 16.

PMID:
22111823
13.

High cut-off renal replacement therapy for removal of myoglobin in severe rhabdomyolysis and acute kidney injury: a case series.

Heyne N, Guthoff M, Krieger J, Haap M, Häring HU.

Nephron Clin Pract. 2012;121(3-4):c159-64. doi: 10.1159/000343564. Epub 2013 Jan 16.

PMID:
23327834
14.

High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy.

Sinisalo M, Silvennoinen R, Wirta O.

Am J Hematol. 2012 Jun;87(6):640. doi: 10.1002/ajh.23189. Epub 2012 Mar 31.

15.

Prolonged hemodialysis for acute kidney injury in myeloma patients.

Hanf W, Guillaume C, Jolivot A, Chapuis-Cellier C, Guebre-Egziabher F, Fontana A, Fouque D, Juillard L.

Clin Nephrol. 2010 Oct;74(4):319-22.

PMID:
20875387
16.

Recovery of kidney function following delayed use of Theralite™ dialyzer in a patient with myeloma cast nephropathy.

Dahal K, Shastri S, Narayanasami U, Bijol V, Rider K, Strom JA, Jaber BL.

Clin Nephrol. 2013 Apr;79(4):318-22. doi: 10.5414/CN107357.

PMID:
22541683
17.

Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.

Borrego-Hinojosa J, Pérez-del Barrio MP, Biechy-Baldan Mdel M, Merino-García E, Sánchez-Perales MC, García-Cortés MJ, Ocaña-Pérez E, Gutiérrez-Rivas P, Liébana-Cañada A.

Nefrologia. 2013;33(4):515-23. doi: 10.3265/Nefrologia.pre2013.Feb.11932. English, Spanish.

18.

Extracorporeal treatment of cast nephropathy.

Gakhar B, Kobrin S, Berns JS.

Semin Dial. 2011 Jan-Feb;24(1):9-11. doi: 10.1111/j.1525-139X.2010.00814.x. Epub 2011 Feb 17.

PMID:
21324000
19.

Management options for cast nephropathy in multiple myeloma.

Cockwell P, Hutchison CA.

Curr Opin Nephrol Hypertens. 2010 Nov;19(6):550-5. doi: 10.1097/MNH.0b013e32833ef72c. Review.

PMID:
20827195
20.

The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.

Cockwell P, Cook M.

Adv Chronic Kidney Dis. 2012 Sep;19(5):324-32. doi: 10.1053/j.ackd.2012.06.003. Review.

PMID:
22920643

Supplemental Content

Support Center